HC Wainwright reissued their buy rating on shares of Kodiak Sciences (NASDAQ:KOD – Free Report) in a report issued on Monday morning, MarketBeat reports. They currently have a $58.00 target price on the stock. HC Wainwright also issued estimates for Kodiak Sciences’ Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($2.01) EPS, FY2029 earnings at $0.18 EPS and FY2030 earnings at $3.04 EPS.
KOD has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. JPMorgan Chase & Co. raised their price objective on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Chardan Capital raised shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $14.00 to $61.00 in a research report on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.14.
Read Our Latest Stock Report on Kodiak Sciences
Kodiak Sciences Stock Performance
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, equities research analysts forecast that Kodiak Sciences will post -3.83 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. Westfuller Advisors LLC purchased a new position in shares of Kodiak Sciences during the first quarter worth $26,000. V Square Quantitative Management LLC purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at $26,000. EverSource Wealth Advisors LLC raised its holdings in shares of Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after buying an additional 916 shares during the period. KBC Group NV acquired a new position in Kodiak Sciences during the 1st quarter worth about $39,000. Finally, GF Fund Management CO. LTD. acquired a new position in Kodiak Sciences during the 4th quarter worth about $29,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Kodiak Sciences News Summary
Here are the key news stories impacting Kodiak Sciences this week:
- Positive Sentiment: HC Wainwright reiterated its Buy rating and $58 price target. Against the quoted share price of about $40, the target indicates substantial potential upside if Kodiak’s pipeline and commercialization plans deliver. HC Wainwright Reiterates Buy Rating for Kodiak Sciences
- Positive Sentiment: Recent coverage characterizes analysts as bullish on healthcare stocks including Kodiak Sciences, reinforcing favorable sentiment around the company despite its ongoing losses. Analysts Are Bullish on These Healthcare Stocks
- Negative Sentiment: HC Wainwright reduced its 2026 EPS estimate to a loss of $3.75 from $3.48, slightly below the $3.74 consensus forecast. Quarterly loss estimates were also lowered to $0.89 per share for both the third and fourth quarters, versus prior estimates of $0.80 and $0.81.
- Negative Sentiment: Longer-term estimates were cut as well: 2027 EPS to a $3.27 loss from $2.92, 2028 to a $2.01 loss from $1.74, 2029 profit to $0.18 from $0.39, and 2030 profit to $3.04 from $3.20. These revisions suggest a slower path to profitability and may be weighing on the shares.
Kodiak Sciences Company Profile
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Read More
- Five stocks we like better than Kodiak Sciences
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
